Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/s0034-98872021000400652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.
JAMA Netw Open
January 2025
Healthcare Transformation Institute, Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Importance: Adherence to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is important for their effectiveness. Discontinuation and reinitiation patterns are not well understood.
Objective: To describe rates of and factors associated with discontinuation and subsequent reinitiation of GLP-1 RAs among adults with overweight or obesity.
Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.
Am J Clin Dermatol
January 2025
Department of Dermatology, The Ohio State University, 1328 Dublin Rd, Suite 100, Columbus, OH, 43212, USA.
Morbilliform eruptions, which are a clinical reaction pattern characterized by erythematous macules and papules coalescing into patches that cover most of the skin surface, are one of the most common cutaneous findings in the inpatient setting. In the hospital setting, most causes are benign and due to low-risk drug exanthems; however, morbilliform eruptions may also be a sign of high-risk diseases, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, acute generalized exanthematous pustulosis, and graft-versus-host disease. Proper identification of the etiology and risk stratification of a morbilliform eruption is critical to ensure proper management and optimize patient outcomes.
View Article and Find Full Text PDFCombining non-invasive brain stimulation techniques and EEG markers analysis: an innovative approach to cognitive health in aging.
Geroscience
January 2025
Brain Connectivity Laboratory, Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele Roma, Rome, Italy.
In an era marked by a rapidly aging global population, delving into the intricate neurophysiological changes that accompany the aging process assumes paramount importance. This narrative review offers a comprehensive exploration of the intricate relationship between electromagnetic neuromodulation and electroencephalography (EEG) within the context of aging. Moreover, it showed the promising landscape of non-invasive neuromodulation techniques, encompassing established methodologies like transcranial magnetic stimulation (TMS) and transcranial direct and alternating current stimulation (tDCS/tACS).
View Article and Find Full Text PDFNocturia as a clinical marker of loss of function and resilience or risk factor for frailty in older adults? Results of the Berlin Aging Study II.
Geroscience
January 2025
Medical Department of Endocrinology and Metabolic Diseaseas (including Lipid Metabolism), Charité-Universitätsmedizin Berlin, Berlin, Germany.
The current study examined cross-sectional and longitudinal associations between nocturia and frailty in a cohort of men and women aged 60 years and older, as evidence on this topic was lacking. We analyzed baseline and follow-up data (n = 1671) from the Berlin Aging Study II (BASE-II), a prospective longitudinal cohort study focusing on the factors associated with "healthy" vs. "unhealthy" aging.
View Article and Find Full Text PDFObecabtagene Autoleucel: First Approval.
Mol Diagn Ther
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Obecabtagene autoleucel (AUCATZYL) is a CD19-directed genetically modified autologous T cell immunotherapy which is being developed by Autolus for the treatment of hematological cancers and systemic lupus erythematosus. In comparison with other chimeric antigen receptor T (CAR T) therapies, obecabtagene autoleucel has a fast off-rate binder for CD19. Obecabtagene autoleucel received approval following positive results from the FELIX phase I/II trial in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and it is the first CAR T therapy that does not have mandatory Risk Evaluation Mitigation Strategy monitoring requirements.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!